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Background: As a poorly water-soluble drug, the oral application of morin is limited by 
its low oral bioavailability. In this study, a new self-nanoemulsifying drug delivery system 
(SNEDDS), based on the phospholipid complex technique, was developed to improve the oral 
bioavailability of morin.
Methods: Morin-phospholipid complex (MPC) was prepared by a solvent evaporation method 
and characterized by infrared spectroscopy and X-ray diffraction. After formation of MPC, it was 
found that the liposolubility of morin was significantly increased, as verified through solubility 
studies. An orthogonal design was employed to screen the blank SNEDDS, using emulsifying 
rate and particle size as evaluation indices. Ternary phase diagrams were then constructed to 
investigate the effects of drug loading on the self-emulsifying performance of the optimized 
blank SNEDDS. Subsequently, in vivo pharmacokinetic parameters of the morin-phospholipid 
complex self-nanoemulsifying drug delivery system (MPC-SNEDDS) were investigated in 
Wistar rats (200 mg/kg of morin by oral administration).
Results: The optimum formulation was composed of Labrafil® M 1944 CS, Cremophor® RH 
40, and Transcutol® P (3:5:3, w/w), which gave a mean particle size of approximately 140 nm. 
Oral delivery of the MPC-SNEDDS exhibited a significantly greater Cmax (28.60 µg/mL) than 
the morin suspension (5.53 µg/mL) or MPC suspension (23.74 µg/mL) (all P , 0.05). Tmax was 
prolonged from 0.48 to 0.77 hours and to 1 hour for MPC and MPC-SNEDDS, respectively. 
In addition, the relative oral bioavailability of morin formulated in the MPC-SNEDDS was 
6.23-fold higher than that of the morin suspension, and was significantly higher than that of 
the MPC suspension (P , 0.05).
Conclusion: The study demonstrated that a SNEDDS combined with the phospholipid complex 
technique was a promising strategy to enhance the oral bioavailability of morin.
Keywords: morin, phospholipid complex, self-nanoemulsifying drug delivery system, oral 
bioavailability
Introduction
Morin (3,5,7,2′,4′-pentahydroxyflavone) is one of the flavonols that has been 
identified in fruits, vegetables, tea, and many medicinal herbs from Asia.1 It has been 
reported to possess anti-inflammatory, anticancer, antioxidant, antihypertensive, and 
anticlastogenic activities.2–6 It has also been found to have an inhibitory effect on 
xanthine oxidase.7 In addition, in a toxicity study of dietary administered morin in 
rats, no mortality or abnormal clinical signs were shown.8International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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However, available pharmacokinetic data in both humans 
and rats are scarce at present. A previous study compared 
the pharmacokinetics between morin and quercetin after 
oral administration but failed to consider the absolute 
  bioavailability of morin.9 As a poorly water-soluble drug, the 
absolute bioavailability of morin after a single oral dose is 
very low (,1%), as determined in the present study. To the 
best of the authors’ knowledge, low oral bioavailability may 
result in decreased efficacy when therapeutic plasma levels 
are not achieved, or may result in unanticipated toxicity at 
a high dose of morin. However, to date, few studies have 
focused on the applicable formulation of morin through 
oral administration. Most studies have used a simple morin 
aqueous solution via parenteral route to obtain the targeted 
pharmacological effect.5,6 Parenteral administration offers 
the best absorption but has obvious disadvantages, such 
as low patient compliance, safety considerations, and high 
medication costs.10 Thus, there is a pressing need to develop a 
new oral dosage form of morin with improved bioavailability 
and, furthermore, to obtain successful therapeutic effects at 
a decreased oral dose.
Various formulation techniques have been developed to 
improve the bioavailability of poorly water-soluble drugs, 
such as solid dispersion, cyclodextrins, emulsions, liposomes, 
and nanoparticles.11 Among these methods, much attention has 
recently been focused on self-nanoemulsifying drug delivery 
systems (SNEDDSs) to improve the oral bioavailability of 
poorly soluble drugs.12–16 For SNEDDSs, isotropic mixtures 
of oils and surfactants are used to form fine oil-in-water 
nanoemulsions when exposed to aqueous media, such as 
gastrointestinal fluids under mild agitation with droplet size 
less than 200 nm.17 Drug delivery advantages offered by 
SNEDDSs include presenting and maintaining the drug in a 
dissolved rate or in small droplets of oil; protection against 
enzymatic hydrolysis; the potential for enhanced absorption 
afforded by surfactant-induced permeability changes; and the 
inhibitory effect on P-glycoprotein (P-gp) activities.18 This 
renders the SNEDDS as a good candidate for oral delivery of 
morin in an attempt to solve its bioavailability problem.
Previous studies have demonstrated that phospholipid 
complexes can improve the liposolubility and the therapeutic 
efficacy of certain drugs with poor oral bioavailability.19–21 In 
this study, a phospholipid complex was prepared to improve 
the liposolubility of morin and facilitate the incorporation of 
morin into a SNEDDS.
Thus, the purpose of this study was to develop a novel 
SNEDDS based on the phospholipid complex technique to 
enhance the oral bioavailability of morin. This is the first 
time, to the authors’ knowledge, that an oral formulation of 
morin was developed to address its bioavailability problem. 
It is hoped that this study not only offers a good example of 
enhancing the oral bioavailability of poorly water soluble 
drugs by the combined use of phospholipid complex and a 
SNEDDS, but also provides a promising oral formulation of 
morin for clinical application.
Materials and methods
Materials
Morin hydrate was purchased from Sigma– Aldrich® (Sigma® 
Chemical, St Louis, MO). Polyoxyl 40 hydrogenated castor 
oil (Cremophor® RH 40), and polyoxyl 35 castor oil 
(Cremophor® EL) were donated by BASF (Ludwigshafen, 
Germany). Oleoyl macrogolglycerides (Labrafil® M 1944 
CS), propylene glycol laurate (Lauroglycol™ FCC), 
propylene glycol monolaurate (Lauroglycol™ 90), and 
diethylene glycol monoethyl ether (Transcutol® P) were 
kindly supplied by Gattefossé China Trading Company 
(Shanghai, People’s Republic of China). Acetonitrile 
of high performance liquid chromatography (HPLC) 
grade was purchased from SK Chemicals (Seoul, South 
Korea). Soya phospholipid was obtained from Lipoid 
(Ludwigshafen, Germany). Benzoic acid and 1,2-propylene 
glycol were purchased from Ruijinte Chemical Co, Ltd 
(Tianjin, China). Tetrahydrofuran was purchased from 
Bioway America (Marlton, NJ). Carboxymethyl cellulose 
sodium, hydrochloric acid, polyoxyethylene sorbitan 
monooleate (Tween® 80), ethanol, and phosphoric acid 
were obtained from Kermel Chemical Reagent Co, Ltd 
(Tianjin, China). All other chemicals were of analytical 
reagent grade.
Preparation of morin-phospholipid 
complex
The morin-phospholipid complex (MPC) was prepared with 
morin and phospholipid at a mass ratio of 1:1.5. Required 
amounts of morin and phospholipids were placed in a 
100-mL round bottom flask, and 30 mL tetrahydrofuran 
was added. The mixture was then stirred with a magnetic 
agitator (Yuhua Instrument Co, Ltd, Gongyi, China) at 40°C 
for 2 hours. Afterwards, a vacuum rotary evaporator (Büchi 
Rotavapor® R-3; Büchi, Switzerland) was used to evaporate 
tetrahydrofuran, and the residue was dried under vacuum for 
24 hours. The resultant MPC was transferred into a glass 
bottle and stored at room temperature.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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characterization of MPc
MPC was verified by Fourier transform infrared spectropho-
tometry (FT-IR Spectrometer IFS-55; Bruker, Fällanden, 
Switzerland) and X-ray diffractometry (D/max-r A; Rigaku 
Denki, Tokyo, Japan). The infrared spectra of morin, MPC, and 
physical mixture of morin and phospholipids were obtained by 
the KBr method. The X-ray diffractogram was scanned with 
the diffraction angle increasing from 0° to 60°, 2θ angle, with 
a step angle of 0.02° and a count time of 0.40 seconds.
Determination of morin content in MPc
The content of morin in the complex was determined by 
HPLC method, established according to a previous study 
with some modifications.9 The analysis was performed on 
a Waters® 2690 HPLC system equipped with a Waters 996 
Photodiode Array Detector (Waters, Milford, MA). A Zorbax 
SB-C18 (Agilent Technologies, Santa Clara, CA) analytical 
column (150 mm × 4.6 mm, 5 µm) was used with a mobile 
phase consisting of acetonitrile and 0.5% phosphoric acid 
(24:76, v/v) by a flow rate of 1.0 mL/min. Detection wave-
length was 252 nm, and the injection volume was 100 µL.
Studies showed that the precision, accuracy, and recovery 
of this HPLC method all met the measurement requirements. 
The linear standard curve (r = 0.9999) was used to determine 
the concentration of morin. All measurements were done in 
triplicate.
solubility studies
Solubility studies were carried out to verify whether the lipo-
solubility of morin was improved after formation of MPC. 
Excess amounts of morin, MPC, and the physical mixture 
of morin and phospholipid were added to 1 mL of water or 
n-octanol in sealed glass containers. The samples were kept 
at 25°C with constant shaking for 48 hours and then centri-
fuged at 5064 × g for 10 minutes using a table-top, high-speed 
centrifuge (TGL-16G; Xingke Scientific Instruments Co, Ltd, 
Hunan, China). Afterward, supernatants were removed and 
suitably diluted with methanol. The concentration of morin 
was determined by the HPLC method mentioned above. Each 
experiment was run in triplicate. Similarly, the solubilities of 
morin and MPC in three different oils (Labrafil M 1944 CS, 
Lauroglycol FCC, and Lauroglycol 90) were determined.
Formulation optimization  
of a blank sNeDDs
The blank SNEDDS formulation was screened by the 
orthogonal design using Labrafil M 1944 CS, Lauroglycol 90, 
and Lauroglycol FCC as oil phase; Cremophor EL, Cremophor 
RH 40, and Tween 80 as surfactants; and   Transcutol P and 
1,2-propylene glycol as cosurfactants. Eighteen different 
combinations were obtained, and nine experiments were 
then performed for each combination. Mixtures of oil, sur-
factants, and cosurfactants at prefixed ratios were placed in 
tubes and vortexed vigorously. After that, certain amounts 
of the mixtures were added to distilled water (v/v, 1:100). 
The mean particle size of the samples was determined by a 
photon correlation spectroscope (Malvern Zetasizer Nano 
ZS90, Malvern Instruments Ltd, Worcestershire, UK). All 
measurements were done in triplicate. The system composed 
of Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P 
was further studied using the particle size and emulsification 
rate as indices.
construction of ternary phase diagram
The self-emulsifying region of the selected system with   different 
drug loading was identified from ternary phase   diagrams. 
A series of self-emulsifying systems with varying concentra-
tions of Labrafil M 1944 CS (5%–40%, v/v),   Cremophor RH 
40 (30%–70%, v/v), Transcutol P (0%–40%, v/v), and morin 
(1%–15%, w/w) was prepared. The samples were then vor-
texed and sonicated until oily liquid mixtures were obtained. 
Each sample was then added dropwise into distilled water (v/v, 
1:100). The self-emulsifying performance of the generated 
samples was visually observed. Samples that showed drug 
precipitation or cracking were rejected. Samples that could 
easily spread in water and form a fine emulsion were judged 
as “good.” Samples were labeled as “bad” when there was 
poor or no emulsion formation with immediate coalescence 
of oil droplets when stirring was stopped.22 Phase diagrams 
were plotted using the above criteria. Finally, the formulation 
composed of Labrafil M 1944 CS, Cremophor RH 40, and 
Transcutol P (3:5:3) with a drug loading of 10% (w/w) was 
selected as the best one of its kind.
characterization of MPc-sNeDDs
The droplet size and polydispersity index of the optimized 
morin-phospholipid complex-SNEDDS (MPC-SNEDDS) 
after dilution with distilled water (1:100, v/v) were 
determined. Morphological features of the MPC-SNEDDS 
were observed by transmission electron microscope (TEM; 
Hitachi H-600; Hitachi Co, Tokyo, Japan). The sample was 
diluted with distilled water at a ratio of 1:100 and mixed by 
gentle shaking. One drop of the sample was then placed on 
copper grids, and any excess was drawn off with filter paper. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The sample was negatively stained by 1% phosphomolybdic 
acid and then subjected to TEM observation.
Pharmacokinetic studies in rats
Animal experiments were conducted in accordance with 
the guidelines of the Institutional Animal Care and Use 
  Committee of Sichuan University (Sichuan, China). Male 
Wistar rats (200–250 g) were provided by the Laboratory 
Animal Center of Sichuan University. Rats were randomly 
divided into four groups (n = 5) and fasted for 12 hours before 
administration of doses. One group was given intravenous 
morin saline solution (1 mg/kg). The other three groups 
were given morin suspension, MPC suspension, or the 
MPC-SNEDDS at 200 mg/kg by gavage. Morin suspension 
and MPC suspension were prepared by dispersing morin 
and MPC in 5% sodium carboxymethyl cellulose solution, 
respectively.
Blood (400 µL) was collected via tail vein into heparinized 
centrifuge tubes at prefixed time points after administration of 
these four dosage forms. Plasma was separated from whole 
blood by centrifugation (1296 × g, 5 minutes) and stored at 
4°C prior to analysis.
Rat plasma (100 µL) was pipetted into a centrifuge 
tube, and then equal amounts of internal standard solution 
containing benzoic acid in methanol, methanol, and 25% 
hydrochloric acid were added sequentially. The resultant 
mixture was vortexed for 5 minutes, hydrolyzed in 50°C 
water bath for 0.5 hours, vortexed again for 1 minute, and 
then centrifuged (12544 × g, 15 minutes). The supernatant 
(100 µL) was injected directly into the HPLC column.
Using the HPLC condition mentioned above, the 
standard curve of morin concentration in plasma was 
established and showed good linearity (r = 0.9996) in the 
range of 0.48–48 µg/mL. The standard curve equation of 
morin in serum was Y = 0.2082X-0.0704 (Y stands for the 
concentration of morin, X stands for the peak area ratio of 
morin to internal standard). The recovery rates of morin 
from high, middle, and low concentration ranges were 
97.8% ± 0.012%, 95.1% ± 0.033%, and 91.2% ± 0.047%, 
respectively. The interday relative standard deviations were 
2.18%, 2.60%, and 2.27% respectively; and the intraday 
relative standard deviations were 3.40%, 3.53%, and 5.10%, 
respectively.
This method was then applied to the pharmacokinetic 
studies. The pharmacokinetic data were processed by DAS 
2.0 software (Mathematical Pharmacology Professional 
Committee of China) to calculate the pharmacokinetic 
parameters. The absolute bioavailability (Fa) and relative 
bioavailability (Fr) were calculated according to the following 
equations:
  F
AUC Dose
AUC Dose
a
test i.v
i.vt est
(%) =
  F
AUC
AUC
r
test
reference
(%) =
AUC is the area under the plasma concentration-time 
curve from time 0 to the last sampling time for both 
equations.
statistical analysis
Student’s t test was used for statistical comparisons between 
the pharmacokinetic data of these three groups. A value of 
P , 0.05 was considered statistically significant.
Results and discussion
characterization of MPc
The formation of MPC was confirmed by infrared spec-
tra and X-ray diffraction. The infrared spectra of morin, 
phospholipid, MPC, and the physical mixture are shown 
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Figure 1 Infrared spectra of (A) morin; (B) phospholipids; (C) morin-phospholipid 
complex; and (D) physical mixture of morin and phospholipids.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in Figure 1. There were significant differences between the 
spectrum of MPC (Figure 1C) and spectrum of the physical 
mixture (Figure 1D). The characteristic absorption peak of 
morin at 1625 cm-1 (νC-C=O) was easily found in the spectrum 
of physical mixture. However, the absorption peak of morin 
had shifted up to 1613 cm-1(νC=O) in the MPC spectrum 
(Figure 1C), indicating interactions between morin and 
  phospholipids. On the other hand, the characteristic absorp-
tion peak of phospholipid was found to be at 1734 cm-1 
(νOH-C=O) in spectrums of both the complex and the physical 
mixture. However, the absorption strength at 1734 cm-1 was 
lessened greatly by the formation of MPC, compared with 
that in the spectrum of phospholipid. In addition, there was 
no new peak observed in the MPC spectrum (Figure 1C).
Figure 2 shows the X-ray diffraction curves of morin, 
phospholipids, MPC, and the physical mixture. The morin 
powder diffraction pattern shown in Figure 2A has obvi-
ous sharp crystalline peaks. In contrast, phospholipids 
appeared to have an amorphous structure, as shown in 
Figure 2B. The crystalline structure of morin remained 
unchanged in the physical mixture (Figure 2D). However, 
as shown in   Figure 2C, the crystalline peaks of MPC had 
disappeared, showing a structural characteristic similar to 
that of   phospholipids. This was probably a consequence of 
  noncovalent interactions between morin and phospholipids, 
such as hydrogen bonding and van der Waals forces. 
The morin molecule was “entrapped” in the polar head 
of   phospholipids molecules, and thus its own crystalline 
  characteristic was inhibited.
The content of morin in the complex determined by 
HPLC was 38.3% (w/w). The result was concordant with 
the reactant ratio of morin and phospholipids.
solubility studies
The enhancement on the liposolubility of morin by 
the   formation of MPC was investigated. As shown in 
Table 1, the solubility of morin in the n-octanol increased 
significantly after the formation of MPC. However, the 
hydrophilicity and lipophilicity of morin was slightly 
improved by the   phospholipids in physical mixture. The 
result indicated that the phospholipids exhibited benefi-
cial effects on the   solubility of morin after the formation 
of MPC. Simultaneously, the solubilities of morin and 
MPC in different types of oils were also investigated. 
Table 2 shows the enhancements on the solubility of morin 
in three types of oils after the formation of MPC. As shown 
in Table 2, the solubility of MPC was significantly higher 
than that of morin, suggesting that the formation of MPC 
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Figure 2 X-ray diffraction pattern of (A) morin; (B) phospholipids; (C) morin-
phospholipid complex; and (D) physical mixture of morin and phospholipids.
Table 1 solubility of morin, MPc, and the physical mixture in 
water and n-octanol at room temperature
Sample Solubility in water  
(μg/mL)a
Solubility in n-octanol   
(mg/mL)a
Morin 
MPc 
Physical mixture
18.42 ± 1.49 
74.43 ± 0.36 
34.40 ± 0.01
11.96 ± 6.71 
.1000 
13.85 ± 0.09
Notes: areported as mean ± standard deviation; n = 3.
Abbreviations: MPc, morin-phospholipid complex; the mixture of phospholipids 
and morin, physical mixture.
Table 2 solubility of morin and MPc in different oils at room 
temperature
Type of oil Solubility (mg/mL)
MPCa Morina
Lauroglycol™ Fcc   20.40 ± 1.43   3.15 ± 0.056
Labrafil® M 1944 cs   27.04 ± 1.38   5.83 ± 0.12
Lauroglycol 90 325.60 ± 52.31 83.30 ± 2.34
Notes: areported as mean ± standard deviation; n = 3.
Abbreviation: MPc, morin-phospholipid complex. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3410
Zhang et al
could drastically facilitate the incorporation of morin into 
a SNEDDS. The solubility of morin in many other oils 
was less than 5 mg/mL, even after MPC formation (data 
not shown).
Development of MPc-sNeDDs
As a simple, fast, and economical method, orthogonal design 
was used to screen the optimum blank SNEDDS. The ratios 
at which the oil, surfactants, and cosurfactants were mixed 
with each other are shown in Table 3. The droplet sizes of 
the resultant translucent nanoemulsions for each combination 
are listed in Table 4.
As shown in Table 4, all of the translucent nanoemulsions 
showed mean droplet sizes in the range of 20–100 nm. 
  Unfortunately, all samples were turbid when Lauroglycol 90 
was used as oil phase. However, translucent nanoemulsions 
can be formed in the case of Labrafil M 1944 CS, which prob-
ably is due to its greater hydrophilicity and surfactant-like 
properties.23 In recent years, many drugs have been reported to 
exhibit significantly higher bioavailability after administration 
of an a long-chain triglyceride (LCT) solution formulation 
than a similar medium-chain triglyceride (MCT) solution, 
probably because of the more effective lymphatic drug trans-
port or more efficient solubilization in the gastrointestinal 
tract by the long-chain lipid digestion product.24 With LCTs, 
there may be a potential advantage with using Labrafil M 1944 
CS as the oil phase. Transcutol P and 1,2-propylene glycol 
were investigated as cosurfactants for their good solubility of 
morin (more than 1 g/mL). The results show that   Transcutol P 
exhibited better self-nanoemulsifying ability due to its greater 
fluidity and compatibility than 1,2-propylene glycol. In 
addition, the formulation composed of Labrafil M 1944 CS, 
  Cremophor RH 40, and Transcutol P at a ratio of 3:5:3 was 
found to have the smallest particle size (28.34 ± 0.03 nm), with 
a narrow size distribution (0.067 ± 0.006), after dilution. Thus, 
the combination of Labrafil M 1944 CS, Cremophor RH 40, 
and Transcutol P was chosen for further study.
Table 4 Droplet size and polydispersity index of sNeDDs formulations after dilution with distilled water at a ratio of 1:100
System Ratio Particle size (nm)a Polydispersity indexa Time of emulsification
Labrafil® M 1944 cs/cremophor® eL/Transcutol® P 3:3:1 35.21 ± 0.79 0.111 ± 0.016 1 min∼3 min
3:4:2 28.73 ± 0.61 0.098 ± 0.013 ,1 min
3:5:3 28.34 ± 0.56 0.067 ± 0.006 ,1 min
4:3:2 33.85 ± 1.21 0.082 ± 0.006 ,1 min
4:4:3 36.92 ± 1.94 0.222 ± 0.031 1 min∼3 min
Labrafil M 1944 CS/Cremophor RH 40/Transcutol P 3:3:1 39.93 ± 0.87 0.099 ± 0.013 ,1 min
3:4:2 30.48 ± 0.74 0.141 ± 0.019 ,1 min
3:5:3 28.34 ± 0.03 0.079 ± 0.003 ,1 min
4:3:2 39.45 ± 1.17 0.093 ± 0.009 ,1 min
4:5:1 29.93 ± 0.92 0.114 ± 0.017 1 min∼3 min
4:4:3 37.20 ± 0.63 0.228 ± 0.039 ,1 min
5:4:1 43.59 ± 1.85 0.101 ± 0.008 1 min∼3 min
5:3:3 76.75 ± 2.16 0.243 ± 0.011 1 min∼3 min
Lauroglycol™ Fcc/cremophor rh 40/Transcutol P 3:3:1 35.69 ± 1.22 0.288 ± 0.039 ,1 min
3:4:2 34.38 ± 0.97 0.101 ± 0.020 ,1 min
3:5:3 32.45 ± 1.13 0.253 ± 0.041 ,1 min
4:4:3 41.93 ± 1.52 0.088 ± 0.002 ,1 min
Lauroglycol Fcc/Tween® 80/1, 2-propylene glycol 4:4:3 37.93 ± 2.90 0.228 ± 0.027 ,1 min
Lauroglycol Fcc/cremophor eL/Transcutol P 3:3:1 57.17 ± 2.03 0.388 ± 0.046 .3 min
Labrafil M 1944 CS/Tween 80/Transcutol P 3:5:3 97.40 ± 4.58 0.267 ± 0.031 ,1 min
Notes: areported as mean ± standard deviation; n = 3.
Table 3 Factors and levels of L9 (33) orthogonal test
Run Oil Surfactant Cosurfactant
1 1 (3) 1 (3) 1 (1)
2 1 (3) 2 (4) 2 (2)
3 1 (3) 3 (5) 3 (3)
4 2 (4) 1 (3) 2 (2)
5 2 (4) 2 (4) 3 (3)
6 2 (4) 3 (5) 1 (1)
7 3 (5) 1 (3) 3 (3)
8 3 (5) 2 (4) 1 (1)
9 3 (5) 3 (5) 2 (2)
Notes: Orthogonal experimental form of L9 (33) was adopted to determine the 
ratios of oil, surfactant, and cosurfactant to be evaluated to a self-nanoemulsifying 
drug delivery system (sNeDDs) formulation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The self-emulsifying performance of the selected SNEDDS 
with varying drug loading was accessed using ternary phase 
diagrams. The results show that the self-emulsification 
region of the formulation decreased on increased drug 
  loading. To obtain a good balance between drug loading and 
efficient emulsification, the formulation composed of 
  Labrafil M 1944 CS, Cremophor RH 40, and Transcutol P 
(3:5:3) with a drug loading of 10% (w/w) was selected. The 
ternary phase diagram of the optimized formulation is shown 
in Figure 3.
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Figure  3  Ternary  phase  diagram  of  the  sNeDDs  formulation  composed 
of the following: oil – Labrafil M 1944 CS; surfactant – Cremophor RH 40; and 
cosurfactant – Transcutol P,  with a drug loading of 10%. 
Notes: The red outline represents the area explored for locating nanoemulsion 
region. The blue area represents nanoemulsion region.
Figure  4  Transmission  electron  microscope  image  of  MPc-loaded  sNeDDs 
formulation. 
Note: scale bar = 200 nm. 
Abbreviations:  MPc,  morin-phospholipid  complex;  MPc-sNeDDs,  morin-
phospholipid complex self-nanoemulsifying drug delivery system.
characterization of MPc-sNeDDs
The prepared MPC-SNEDDS gave a mean particle size of 
140.40 nm after dilution with distilled water. No precipita-
tion of the drug was found when the sample was kept for 
12 hours at 25°C. As shown in the TEM image (Figure 4), 
the SNEDDS prepared in the optimized formulation appears 
to have spherical particles after dilution.
Pharmacokinetic results
The selectivity of the HPLC method was evaluated 
before conduction of the pharmacokinetic study. Figure 5 
illustrates the chromatography of morin. Under the HPLC 
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condition, the chromatograms show that there was no 
endogenous peaks interfering with morin or the inter-
nal standard. In addition, morin peaks can be separated 
well from benzoic acid peaks without any interference. 
The plasma concentration of morin after intravenous 
  administration is shown in Figure 6.   Intravenous data were 
used to calculate the absolute bioavailability of morin after 
oral administration of morin suspension, MPC suspension, 
and the MPC-SNEDDS. The plasma concentration-time 
curves of morin after oral administration are shown in 
  Figure 7. As shown, the MPC-SNEDDS formulation-treated 
rat group had the highest concentration of morin in the 
plasma among the three groups during 0–5 hours (Figure 7). 
The oral   pharmacokinetic parameters are summarized in 
Table 5. It was notable that the Cmax of the MPC-SNEDDS 
(28.60 µg/mL) group was significantly higher than the 
morin suspension (5.53 µg/mL) and MPC suspension 
(23.74 µg/mL) groups. Compared with the morin suspen-
sion, Tmax was prolonged from 0.48 to 0.77 hours and 1 hour 
for the MPC and the MPC-SNEDDS groups, respectively. 
Compared to the morin suspension, the mean relative 
bioavailabilities of the MPC and the MPC-SNEDDS were 
541.73% and 722.84%, respectively.
To the authors’ knowledge, the in vivo tests are the first 
to report the absolute bioavailability of morin, which was 
only 0.45%. It was assumed that the low oral bioavailability 
of morin may be caused by its low aqueous solubility 
(0.25 mg/mL, distilled water, 25°C), P-gp-mediated efflux, 
and low intestinal permeability (Papp = 0.62 nm/s).25 The 
absolute bioavailability of morin in rats was significantly 
increased by the MPC-SNEDDS compared to the morin 
and MPC suspensions. Reasons for this may include the 
  following: (1) After oral administration, the intestinal 
mixing of the excipients, their digestion products, and bile 
components leads to the formation of mixed micelles and 
vesicles, thus improving the solubilization power of the 
gastrointestinal tract components;26 (2) The presence of a 
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Figure  6  Plasma  concentration-time  curve  after  intravenous  administration  of 
morin in Wistar rats (n = 5) at a dose of 1 mg/kg.
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Figure 7 Mean plasma concentration-time profiles of morin in Wistar rats (n = 5) 
after oral administration of morin, MPc, and MPc-sNeDDs formulation at a dose 
of 200 mg/kg. 
Abbreviations: MPc, morin-phospholipid complex; MPc-sNeDDs,  morin-phospholipid 
complex self-nanoemulsifying drug delivery system.
Table 5 Bioavailability and pharmacokinetic parameters (mean ± standard deviation) of morin in Wistar rats after oral administration 
of morin, MPc, and MPc-sNeDDs at a dose of 200 mg/kg (n = 5)
Intravenous morin (1 mg/kg) Oral morin Oral MPC Oral MPC-SNEDDS
AUc0-t (mg/L h) 11.89 ± 0.21 10.64 ± 1.9 57.64 ± 17.19** 76.91 ± 23.77**,##
MrT0-t (h) 1.33 ± 0.32 1.91 ± 0.28 1.87 ± 0.18 2.12 ± 0.01#
Tmax (h) 0.05 ± 0.00 0.48 ± 0.17 0.77 ± 0.27* 1.00 ± 0.47**,#
cmax (µg/mL) 13.86 ± 3.91 5.53 ± 2.07 23.74 ± 3.87** 28.60 ± 9.25**,#
Fa (%) 100.00 0.45 2.42 3.24
Fr (%) – 100 541.73 722.84
Notes: *P , 0.05 compared with morin group; **P , 0.01 compared with morin group; #P , 0.05 MPc-sNeDDs group compared with MPc group; ##P , 0.01 MPc-
sNeDDs compared with MPc group. 
Abbreviations: Fa,  absolute bioavailability; MrT, mean retention time; MPc, morin-phospholipid complex; MPc-sNeDDs, morin-phospholipid complex self-nanoemulsifying 
drug delivery system; Fr, relative bioavailability.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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sNeDDs loaded with morin-phospholipid complex
SNEDDS can act as an intestinal permeability enhancer, 
which may result in increased absorption of morin via para-
cellular or transcellular routes;27,28 (3) Cremophor RH 40 and 
Transcutol P can inhibit the activity of the intestinal efflux 
pump (P-gp), and thus increase the absorption of morin in 
the gastrointestinal tract. Details on the potential effects of 
nonionic surfactants and cosurfactants on P-gp activity have 
also been published in other literature.29,30
The interaction between the MPC-SNEDDS   formulation 
and the biological environment is rather complicated, and 
consequently, the definite absorption mechanisms and the 
potential toxicity of the MPC-SNEDDS requires further 
investigation.
Conclusion
In this study, a MPC-loaded SNEDDS for oral administration 
was successfully developed. The phospholipid   complex 
  significantly improved the liposolubility of morin. 
The   optimum SNEDDS formulation was a mixture of Labrafil 
M 1944 CS, Cremophor RH 40, and Transcutol P at a ratio 
of 3:5:3 (w/w/w). The absolute bioavailability of morin 
increased about 6.2-fold after oral administration of the MPC-
SNEDDS, compared with that of the morin suspension. This 
study represents initial efforts to develop a promising oral 
formulation of morin. In addition, it supports the technique of 
using a SNEDDS combined with the phospholipid complex 
technique as a promising delivery system to enhance the oral 
absorption of poorly water-soluble drugs.
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